Sector: Health Care
JADE BIOSCIENCES INC · Meeting: June 9, 2026
Directors FOR
1
Directors AGAINST
1
Say on Pay
AGAINST
Auditor
FOR
Election of Class II Directors
Against Analysis
Mr. Frohlich joined the board in April 2025 — within the 24-month exemption window — however, as CEO and President he is the company's chief executive and bears direct responsibility for the company's strategic direction; the stock has lost approximately 96% over three years while the XBI — SPDR S&P Biotech ETF gained 60.7% over the same period, a gap of -156.7 percentage points that far exceeds the 30-percentage-point trigger threshold for companies with negative absolute three-year returns; given his role as chief executive, this extraordinary underperformance warrants an AGAINST vote on his director seat even though his formal board tenure began within the exemption window, as the policy requires executive directors to be evaluated on the same TSR basis as all other directors.
For Analysis
Dr. Cain joined the board in April 2025 (less than 24 months ago), which exempts him from the stock performance trigger under policy; he brings relevant healthcare investment and biotech board experience, and no other disqualifying factors apply.
Two Class II directors are up for election: Christopher Cain (independent, exempt from TSR trigger due to tenure under 24 months) receives a FOR vote; Tom Frohlich (CEO/President) receives an AGAINST vote because the company's stock has collapsed approximately 96% over three years while the XBI — SPDR S&P Biotech ETF rose roughly 61%, a gap of -156.7 percentage points that vastly exceeds the 30-percentage-point trigger threshold applicable to companies with negative absolute three-year returns.
CEO
Tom Frohlich
Total Comp
$9,799,759
Prior Support
N/A
The CEO received total compensation of approximately $9.8 million in 2025, driven primarily by $8.8 million in stock option awards — a very large equity grant for a clinical-stage biotech with a $1.3 billion market cap — while the stock declined roughly 71% in the past year and approximately 96% over three years, during which the XBI — SPDR S&P Biotech ETF gained about 61%, a gap of -156.7 percentage points; this represents severe pay-for-performance misalignment because the incentive compensation was awarded at well above typical levels for this market cap band at the same time shareholders experienced catastrophic losses relative to biotech peers. Although the company discloses a clawback policy and reasonable pay structure features (multi-year vesting, independent compensation committee), the combination of outsized equity grants and extreme underperformance versus the XBI — SPDR S&P Biotech ETF triggers an AGAINST vote under the policy's pay-for-performance alignment check.
Auditor
PricewaterhouseCoopers LLP
Tenure
1 yrs
Audit Fees
$1,520,000
Non-Audit Fees
$2,500
PwC was appointed in April 2025, so its tenure is approximately one year — well below the 25-year threshold that would raise independence concerns; non-audit fees of $2,500 represent less than 1% of audit fees of $1,520,000, far below the 50% threshold; PwC is a Big 4 firm appropriate for a $1.3 billion company; no restatements or other disqualifying factors are present.
The 2026 Jade Biosciences annual meeting presents three proposals: director elections are split (FOR Dr. Cain, AGAINST Mr. Frohlich as CEO due to catastrophic TSR underperformance versus the XBI — SPDR S&P Biotech ETF), the auditor ratification of newly appointed PwC is straightforward and earns a FOR, while Say on Pay earns an AGAINST given $9.8 million in CEO compensation — overwhelmingly equity grants — awarded against a backdrop of approximately 96% stock price decline and -156.7 percentage point underperformance versus the XBI — SPDR S&P Biotech ETF; the jury waiver charter amendment also earns an AGAINST as it removes a key shareholder protection right in fiduciary duty claims with no clear offsetting shareholder benefit.
